Upadacitinib

Common brands: Rinvoq, Methotrexate, Rasuvo, Otrexup, Trexall

Top reporter: Abbvie Inc.

Janus Kinase Inhibitor [EPC]Corticosteroid [EPC]Folate Analog Metabolic Inhibitor [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Vitamin C [EPC]
76,996
Total Reports
70,308
Serious Reports
2,843
Death Reports
30
Reported Reactions
Death Report Ratio: Moderate (3.69%)

Patient Demographics

Male
21,407
Female
50,450

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Upadacitinib.

# Reaction Reports % of Total
1 PAIN 5,132
8.1%
2 ARTHRALGIA 4,538
7.2%
3 DRUG INEFFECTIVE 4,403
7.0%
4 COVID-19 3,175
5.0%
5 RHEUMATOID ARTHRITIS 3,152
5.0%
6 PAIN IN EXTREMITY 2,692
4.3%
7 FATIGUE 2,552
4.0%
8 SURGERY 2,396
3.8%
9 FALL 2,385
3.8%
10 HEADACHE 1,873
3.0%
11 PNEUMONIA 1,858
2.9%
12 THERAPY INTERRUPTED 1,800
2.8%
13 DEATH 1,784
2.8%
14 DIARRHOEA 1,692
2.7%
15 BACK PAIN 1,673
2.6%
16 PERIPHERAL SWELLING 1,649
2.6%
17 NAUSEA 1,641
2.6%
18 URINARY TRACT INFECTION 1,628
2.6%
19 OFF LABEL USE 1,573
2.5%
20 ILLNESS 1,555
2.5%
21 NASOPHARYNGITIS 1,543
2.4%
22 MALAISE 1,487
2.4%
23 MUSCULOSKELETAL STIFFNESS 1,470
2.3%
24 RASH 1,470
2.3%
25 DYSPNOEA 1,421
2.2%
26 ACNE 1,409
2.2%
27 PYREXIA 1,373
2.2%
28 KNEE ARTHROPLASTY 1,342
2.1%
29 JOINT SWELLING 1,337
2.1%
30 INFECTION 1,245
2.0%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.